Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05495464
Title A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

mantle cell lymphoma

Therapies

Cyclophosphamide + Fludarabine

Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine

Acalabrutinib + Rituximab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST